You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)自研新藥XH-S004在內地治療COPD啟動Ib期臨床試驗
阿思達克 07-17 17:44
復星醫藥(02196.HK)公布,控股子公司星浩澎博自主研發的1類新藥XH-S004用於治療慢性阻塞性肺疾病(COPD)適應症於近日在中國境內(不包括港澳台地區)啟動Ib期臨床試驗。 公司指,XH-S004為復星醫藥自主研發的小分子口服二(月太)基(月太)(酉每)1(DPP-1)抑制劑,擬用於治療COPD、非囊性纖維化支氣管擴張症等。XH-S004 另一適應症用於治療非囊性纖維化支氣管擴張症在中國境內處於II期臨床試驗階段。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account